Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
32.18 EUR | -3.01% |
|
-2.90% | +9.12% |
07:58am | AXA : Receives a Buy rating from Barclays | ZD |
Jun. 07 | Federal states want to promote compulsory insurance against natural hazards | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Its low valuation, with P/E ratio at 9.5 and 8.73 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.12% | 78.94B | B- | ||
+7.28% | 50.45B | B | ||
+5.07% | 49.81B | B+ | ||
+21.62% | 46.31B | B+ | ||
+12.83% | 42.31B | B+ | ||
+23.53% | 39.83B | B | ||
-1.53% | 28.46B | B | ||
-8.80% | 27.07B | B- | ||
+27.21% | 26.32B | A | ||
-18.46% | 25.51B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CS Stock
- Ratings AXA